知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.019 seconds)

    5-Lipoxygenase-Activating Protein Inhibitor
    1.
    发明申请
    5-Lipoxygenase-Activating Protein Inhibitor 有权
    5-脂氧合酶活化蛋白抑制剂

    公开(公告)号：US20090291981A1

    公开(公告)日：2009-11-26

    申请号：US12471106

    申请日：2009-05-22

    Applicant: Kevin Murray SCHAAB ,  Christopher David KING ,  Nicholas Simon STOCK

    Inventor： Kevin Murray SCHAAB ,  Christopher David KING ,  Nicholas Simon STOCK

    IPC: A61K31/444 ,  C07D401/14 ,  A61P11/06

    CPC classification number: C07D401/14 ,  A61K31/444

    Abstract: Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

    Abstract translation: 本文描述的是FLAP抑制剂3- [3-叔丁基硫烷基-1- [4-（6-乙氧基 - 吡啶-3-基） - 苄基] -5-（5-甲基 - 吡啶-2-基甲氧基）-1H - 吲哚-2-基] -2,2-二甲基 - 丙酸或其药学上可接受的盐。 还描述了制备FLAP抑制剂或其药学上可接受的盐，包括溶剂化物及其多晶型物的方法。 本文还描述了适用于向包括FLAP抑制剂或其药学上可接受的盐的哺乳动物施用的药物组合物，以及使用这些药物组合物治疗呼吸道疾病或其它白三烯依赖性或白细胞三烯介导的病症的方法 或疾病。

    5-lipoxygenase activating protein (FLAP) inhibitor
    2.
    发明授权
    5-lipoxygenase activating protein (FLAP) inhibitor 失效
    5-脂氧合酶激活蛋白（FLAP）抑制剂

    公开(公告)号：US08697730B2

    公开(公告)日：2014-04-15

    申请号：US12257876

    申请日：2008-10-24

    Applicant: Melissa Virginia Rewolinski ,  Kevin Murray Schaab ,  Christopher David King ,  Nicholas Simon Stock

    Inventor： Melissa Virginia Rewolinski ,  Kevin Murray Schaab ,  Christopher David King ,  Nicholas Simon Stock

    IPC: A61K31/44 ,  A61K31/405 ,  C07D401/00 ,  C07D209/02

    CPC classification number: C07D401/10 ,  C07D401/14

    Abstract: Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

    Abstract translation: 本文描述的是合成3- [5-（吡啶-2-基甲氧基）-3-（2-甲基-2-丙硫基）-1- [4-（2-甲氧基吡啶-5-基）苄基] - 吲哚-2-基] -2,2-二甲基 - 丙酸，其药学上可接受的盐，药学上可接受的溶剂合物。 还描述了适用于哺乳动物的口服给药的药物组合物，以及使用这些口服药物组合物治疗呼吸道疾病或其它白三烯依赖性或白细胞三烯介导的病症或疾病的方法。

    5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR
    4.
    发明申请
    5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR 审中-公开
    5-LIPOXYGENASE-活化蛋白抑制剂

    公开(公告)号：US20110160249A1

    公开(公告)日：2011-06-30

    申请号：US12993319

    申请日：2009-05-22

    Applicant: Kevin Murray Schaab ,  Christopher David King ,  Nicholas Simon Stock

    Inventor： Kevin Murray Schaab ,  Christopher David King ,  Nicholas Simon Stock

    IPC: A61K31/444 ,  C07D401/14 ,  A61P11/06 ,  A61P11/00 ,  A61P9/00

    CPC classification number: C07D401/14 ,  A61K31/444

    Abstract: A pharmaceutically acceptable salt comprising 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate as the anion and a cation selected from Na+, K+, Li+, Ca2+, NH4+, the protonated form of dicyclohexylamine, the protonated form of N-methyl-D-glucamine, the protonated form of tris(hydroxymethyl)methylamine, the protonated form of arginine, and the protonated form of lysine is disclosed, along with formulations and methods of using the same.

    Abstract translation: 包含3- [3-叔丁基硫烷基-1- [4-（6-乙氧基 - 吡啶-3-基） - 苄基] -5-（5-甲基 - 吡啶-2-基甲氧基） 吲哚-2-基] -2,2-二甲基 - 丙酸酯和选自Na +，K +，Li +，Ca 2+，NH 4 +，质子化形式的二环己基胺，质子化形式的N-甲基-D-葡萄糖胺， 公开了三（羟甲基）甲胺的质子化形式，精氨酸的质子化形式和赖氨酸的质子化形式，以及使用它们的制剂和方法。

    5-lipoxygenase-activating protein inhibitor
    6.
    发明授权
    5-lipoxygenase-activating protein inhibitor 有权
    5-脂氧合酶激活蛋白抑制剂

    公开(公告)号：US08772495B2

    公开(公告)日：2014-07-08

    申请号：US12471106

    申请日：2009-05-22

    Applicant: Kevin Murray Schaab ,  Nicholas Simon Stock

    Inventor： Kevin Murray Schaab ,  Nicholas Simon Stock

    IPC: C07D401/14 ,  A61K31/444

    CPC classification number: C07D401/14 ,  A61K31/444

    Abstract: Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

    Abstract translation: 本文描述的是FLAP抑制剂3- [3-叔丁基硫烷基-1- [4-（6-乙氧基 - 吡啶-3-基） - 苄基] -5-（5-甲基 - 吡啶-2-基甲氧基）-1H - 吲哚-2-基] -2,2-二甲基 - 丙酸或其药学上可接受的盐。 还描述了制备FLAP抑制剂或其药学上可接受的盐，包括溶剂化物及其多晶型物的方法。 本文还描述了适用于向包括FLAP抑制剂或其药学上可接受的盐的哺乳动物施用的药物组合物，以及使用这些药物组合物治疗呼吸道疾病或其它白三烯依赖性或白细胞三烯介导的病症的方法 或疾病。

Patent Agency Ranking